Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities (THIRd). An Observational, Prospective, Multicentre, Cohort Study on Italian Patients With Haemophilia A in Prophylaxis Treatment With Turoctocog Alfa Under Current Clinical Conditions

NCT04584892 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT04584892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04584892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities (THIRd). An Observational, Prospective, Multicentre, Cohort Study on Italian Patients With Haemophilia A in Prophylaxis Treatment With Turoctocog Alfa Under Current Clinical Conditions
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
April 12, 2021
Completion date
March 27, 2023
Enrollment
18 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilia a